Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201709-11 Preclinical studies of a novel anti-cancer bispecific antibody CKD-702(Oncology, Protein) [2019-05-27]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

The objective is to carry out preclinical studies, including the efficacy, safety and safety of CKD-702, and thereby obtain Phase 1 clinical IND approval.

CKD-702 is a first-in-class global biopharmaceutical drug with excellent anticancer activity by simultaneously inhibiting EGFR and c-MET, which cause cancer cell proliferation and anticancer drug resistance.

Unmet Medical Need & Target Patients

1) Unmet medical needs

 - Despite the initial high response rates, EGFR-targeted therapies are resistant to about 1 year in most patients. It is necessary to develop a therapeutic agent that overcomes the resistance of the EGFR target therapeutic agent and increases the survival rate.

- c-MET is known to be the major cause of resistance to EGFR target therapeutics. Drug development is required to block EGFR and c-MET simultaneously.

2) Target patient group: Non-small cell lung cancer patient

Status

1) Confirmation of excellent anti-cancer effect of CKD-702 compared to competitive drugs

2) GLP toxicity study underway

3) Manufactured MCB (Master Cell Bank)

4) Clinical drug manufacturing process is under development

5) Completed establishment of standards and test methods

Intellectual Property

1) Patent: New anti-c-Met antibodies and uses thereof

2) Application Status: Completed domestic patent application (10-2017-0067106)

Competitive Advantages

1) The c-MET antibody of CKD-702 differs from the existing developed antibody in its binding site and differentiated from competitors in terms of efficacy and mechanism of action.

2) The EGFR antibody of CKD-702 has low binding affinity to EGFR, resulting in low skin-

related side effects.

3) CKD-702 has excellent anticancer activity in various cancer cell lines, and it is confirmed that it can be developed not only for lung cancer, but also for solid cancer treatment such as stomach cancer.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code